Adicet Bio (ACET) to Release Earnings on Tuesday

Adicet Bio (NASDAQ:ACET) is expected to issue its quarterly earnings data before the market opens on Tuesday, March 18th. Analysts expect the company to announce earnings of ($0.36) per share for the quarter.

Adicet Bio (NASDAQ:ACET) last issued its earnings results on Thursday, March 6th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.05. On average, analysts expect Adicet Bio to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Adicet Bio Trading Up 0.9 %

Shares of ACET opened at $0.78 on Friday. The business’s 50 day moving average is $0.91 and its 200 day moving average is $1.13. The company has a market capitalization of $64.71 million, a PE ratio of -0.46 and a beta of 1.97. Adicet Bio has a 12-month low of $0.74 and a 12-month high of $2.43.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. HC Wainwright reissued a “neutral” rating on shares of Adicet Bio in a research note on Friday, March 7th. StockNews.com downgraded Adicet Bio from a “hold” rating to a “sell” rating in a research note on Tuesday, November 19th. Finally, JMP Securities reissued a “market perform” rating on shares of Adicet Bio in a research note on Thursday, February 6th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, Adicet Bio presently has an average rating of “Hold” and an average price target of $7.50.

About Adicet Bio

Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.